Literature DB >> 29525346

NKG2D and its ligands in cancer.

Payal Dhar1, Jennifer D Wu2.   

Abstract

NKG2D is an activating immune receptor expressed by NK and effector T cells. Induced expression of NKG2D ligand on tumor cell surface during oncogenic insults renders cancer cells susceptible to immune destruction. In advanced human cancers, tumor cells shed NKG2D ligand to produce an immune soluble form as a means of immune evasion. Soluble NKG2D ligands have been associated with poor clinical prognosis in cancer patients. Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years. In this review, we will discuss the progress and perspectives.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29525346      PMCID： PMC6145810          DOI： 10.1016/j.coi.2018.02.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  78 in total

1.  Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D.

Authors:  Gopalakrishnan M Venkataraman; Dominic Suciu; Veronika Groh; Jeremy M Boss; Thomas Spies
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

Review 2.  Advances in NKG2D ligand recognition and responses by NK cells.

Authors:  Nina Le Bert; Stephan Gasser
Journal:  Immunol Cell Biol       Date:  2014-01-21       Impact factor: 5.126

3.  Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D.

Authors:  Noam Stern-Ginossar; Chamutal Gur; Moshe Biton; Elad Horwitz; Moran Elboim; Noa Stanietsky; Michal Mandelboim; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

Review 4.  Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.

Authors:  Ahmed El-Gazzar; Veronika Groh; Thomas Spies
Journal:  J Immunol       Date:  2013-08-15       Impact factor: 5.422

5.  A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.

Authors:  Yu-Hsiang Chang; John Connolly; Noriko Shimasaki; Kousaku Mimura; Koji Kono; Dario Campana
Journal:  Cancer Res       Date:  2013-01-09       Impact factor: 12.701

6.  Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.

Authors:  Gang Xiao; Xuanjun Wang; Jun Sheng; Shengjun Lu; Xuezhong Yu; Jennifer D Wu
Journal:  J Hematol Oncol       Date:  2015-02-20       Impact factor: 17.388

7.  Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.

Authors:  Maulik Vyas; Silke Reinartz; Nathalie Hoffmann; Katrin S Reiners; Sonja Lieber; Julia M Jansen; Uwe Wagner; Rolf Müller; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2017-08-21       Impact factor: 8.110

8.  MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells.

Authors:  Christian Breunig; Jens Pahl; Moritz Küblbeck; Matthias Miller; Daniela Antonelli; Nese Erdem; Cornelia Wirth; Rainer Will; Alexander Bott; Adelheid Cerwenka; Stefan Wiemann
Journal:  Cell Death Dis       Date:  2017-08-03       Impact factor: 8.469

9.  Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma.

Authors:  C S Vetter; W Lieb; E-B Bröcker; J C Becker
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

10.  Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Authors:  Jingyu Zhang; Dai Liu; Guangfu Li; Kevin F Staveley-O'Carroll; Julie N Graff; Zihai Li; Jennifer D Wu
Journal:  Sci Adv       Date:  2017-05-17       Impact factor: 14.136
View more
  43 in total

Review 1.  Dickkopf1: An immunomodulatory ligand and Wnt antagonist in pathological inflammation.

Authors:  Wook-Jin Chae; Alfred L M Bothwell
Journal:  Differentiation       Date:  2019-06-12       Impact factor: 3.880

Review 2.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 3.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

4.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

Authors:  Ye Li; David L Hermanson; Branden S Moriarity; Dan S Kaufman
Journal:  Cell Stem Cell       Date:  2018-06-28       Impact factor: 24.633

5.  Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.

Authors:  Lucas Ferrari de Andrade; Sushil Kumar; Adrienne M Luoma; Yoshinaga Ito; Pedro Henrique Alves da Silva; Deng Pan; Jason W Pyrdol; Charles H Yoon; Kai W Wucherpfennig
Journal:  Cancer Immunol Res       Date:  2020-03-24       Impact factor: 11.151

Review 6.  Targeting innate sensing in the tumor microenvironment to improve immunotherapy.

Authors:  Zhida Liu; Chuanhui Han; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2019-12-16       Impact factor: 11.530

Review 7.  Placental extracellular vesicles and pre-eclampsia.

Authors:  Jessica Schuster; Shi-Bin Cheng; James Padbury; Surendra Sharma
Journal:  Am J Reprod Immunol       Date:  2020-07-18       Impact factor: 3.886

8.  Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.

Authors:  Burak Kucuk; Esra Yilmaz; Ercan Cacan
Journal:  Mol Biol Rep       Date:  2021-05-19       Impact factor: 2.316

9.  T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.

Authors:  Yu-Yang Ng; Johan C K Tay; Zhendong Li; Junjian Wang; Jiangqing Zhu; Shu Wang
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

10.  Immune Responses Vary in Preinvasive Colorectal Lesions by Tumor Location and Histology.

Authors:  Kristin Wallace; Georges J El Nahas; Christine Bookhout; Jessica E Thaxton; David N Lewin; Nana Nikolaishvili-Feinberg; Stephanie M Cohen; J Grant Brazeal; Elizabeth G Hill; Jennifer D Wu; John A Baron; Alexander V Alekseyenko
Journal:  Cancer Prev Res (Phila)       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.